Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Cardiovascular disease

Cardiovascular disease

05-10-2018 | Devices and technology | Review | Article

Diabetes care in the digital era: A synoptic overview

Fatehi F, Menon A, Bird D. Curr Diab Rep 2018; 18: 38. doi: 10.1007/s11892-018-1013-5

05-09-2018 | Sleep apnea | Review | Article

Maternal non-glycemic contributors to fetal growth in obesity and gestational diabetes: Spotlight on lipids

Barbour LA, Hernandez TL. Curr Diab Rep 2018; 18: 37. doi: 10.1007/s11892-018-1008-2

05-08-2018 | Type 2 diabetes | Review | Article

Type 2 diabetes in youth: New lessons from the SEARCH study

Jensen ET, Dabelea D. Curr Diab Rep 2018; 18: 36. doi: 10.1007/s11892-018-0997-1

05-08-2018 | Mental health | Article

The effectiveness of stress management training on blood glucose control in patients with type 2 diabetes

Zamani-Alavijeh F et al. Diabetol Metab Syndr 2018; 10: 39. doi: 10.1186/s13098-018-0342-5

05-08-2018 | Obesity | Review | Article

Obesity prevention: Strategies and challenges in Latin America

Cominato L et al. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0311-1

11-13-2017 | Vildagliptin | Article

Factors that may account for cardiovascular risk reduction with a dipeptidyl peptidase-4 inhibitor, vildagliptin, in young patients with type 2 diabetes mellitus

Evans M et al. Diabetes Ther 2017; 9: 27–36. doi: 10.1007/s13300-017-0329-5

11-03-2017 | Cardiovascular disorders | Review | Article

Modifiable risk factors for cardiovascular disease in children with type 1 diabetes: Can early intervention prevent future cardiovascular events?

Gourgari E, Dabelea D, Rother K. Curr Diab Rep 2017; 17: 134. doi: 10.1007/s11892-017-0968-y

11-01-2017 | Adolescents | News

No renal benefits of ACE inhibitor, statin treatment in adolescents with type 1 diabetes

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

Previous